Walter K. Mowel

Walter K. Mowel

Auto-generated profile, based on publicly available information

Walter K. Mowel

Yale University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AVAnthony T. Virtue
Anthony T. Virtue
SMSam J. McCright
Sam J. McCright
JWJasmine M. Wright
Jasmine M. Wright
MJMonica T. Jimenez
Monica T. Jimenez
WMWalter K. Mowel
Walter K. Mowel
JHJorge Henao-Mejia
Jorge Henao-Mejia
Tryptophan-derived metabolites from the gut microbiota control miR-181 expression in mouse white adipocytes to regulate metabolism and inflammation.

15 August 2016 in Nature
Verified
Journal Article
Open access
PDF file
JKJonathan J. Kotzin
Jonathan J. Kotzin
SSSean P. Spencer
Sean P. Spencer
SMSam J. McCright
Sam J. McCright
DKDinesh B. Uthaya Kumar
Dinesh B. Uthaya Kumar
MCMagalie A. Collet
Magalie A. Collet
JHJorge Henao-Mejia
Jorge Henao-Mejia
The long non-coding RNA Morrbid controls myeloid cell lifespan and regulates apoptosis by repressing the adjacent pro-apoptotic Bcl2l11 gene in cis. Neutrophils, eosinophils and 'classical' monocytes are a first line of defense against pathogens, but their actions can also cause inflammatory diseases. It is important that the lifespan of these myeloid cells is regulated in order to minimize deleterious effects. Jorge Henao-Mejia and colleagues show here that a long non-coding RNA termed Morrbid specifically controls the lifespan of short-lived myeloid cells by regulating expression of the pro-apoptotic Bcl2l11 (Bim) gene. MORRBID is present in humans and is highly upregulated in human hypereosinophilic diseases, so its inhibition may represent a novel therapeutic approach in pathologies influenced by altered myeloid lifespan. Neutrophils, eosinophils and ‘classical’ monocytes collectively account for about 70% of human blood leukocytes and are among the shortest-lived cells in the body1,2. Precise regulation of the lifespan of these myeloid cells is critical to maintain protective immune responses and minimize the deleterious consequences of prolonged inflammation1,2. However, how the lifespan of these cells is strictly controlled remains largely unknown. Here we identify a long non-coding RNA that we termed Morrbid, which tightly controls the survival of neutrophils, eosinophils and classical monocytes in response to pro-survival cytokines in mice. To control the lifespan of these cells, Morrbid regulates the transcription of the neighbouring pro-apoptotic gene, Bcl2l11 (also known as Bim), by promoting the enrichment of the PRC2 complex at the Bcl2l11 promoter to maintain this gene in a poised state. Notably, Morrbid regulates this process in cis, enabling allele-specific control of Bcl2l11 transcription. Thus, in these highly inflammatory cells, changes in Morrbid levels provide a locus-specific regulatory mechanism that allows rapid control of apoptosis in response to extracellular pro-survival signals. As MORRBID is present in humans and dysregulated in individuals with hypereosinophilic syndrome, this long non-coding RNA may represent a potential therapeutic target for inflammatory disorders characterized by aberrant short-lived myeloid cell lifespan.

1 January 2018 in Trends in Immunology
Verified
Journal Article
Closed access
WMWalter K. Mowel
Walter K. Mowel
JKJonathan J. Kotzin
Jonathan J. Kotzin
SMSam J. McCright
Sam J. McCright
VNVanessa D. Neal
Vanessa D. Neal
JHJorge Henao-Mejia
Jorge Henao-Mejia

1 January 2014 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
KGKristin A. Gabor
Kristin A. Gabor
MGMichelle F. Goody
Michelle F. Goody
WMWalter K. Mowel
Walter K. Mowel
MBMeghan E. Breitbach
Meghan E. Breitbach
RGRemi L. Gratacap
Remi L. Gratacap
CKCarol H. Kim
Carol H. Kim
Seasonal influenza virus infections cause annual epidemics and sporadic pandemics. These present a global health concern, resulting in substantial morbidity, mortality and economic burdens. Prevention and treatment of influenza illness is difficult due to the high mutation rate of the virus, the emergence of new virus strains and increasing antiviral resistance. Animal models of influenza infection are crucial to our gaining a better understanding of the pathogenesis of and host response to influenza infection, and for screening antiviral compounds. However, the current animal models used for influenza research are not amenable to visualization of host-pathogen interactions or high-throughput drug screening. The zebrafish is widely recognized as a valuable model system for infectious disease research and therapeutic drug testing. Here, we describe a zebrafish model for human influenza A virus (IAV) infection and show that zebrafish embryos are susceptible to challenge with both influenza A strains APR8 and X-31 (Aichi). Influenza-infected zebrafish show an increase in viral burden and mortality over time. The expression of innate antiviral genes, the gross pathology and the histopathology in infected zebrafish recapitulate clinical symptoms of influenza infections in humans. This is the first time that zebrafish embryos have been infected with a fluorescent IAV in order to visualize infection in a live vertebrate host, revealing a pattern of vascular endothelial infection. Treatment of infected zebrafish with a known anti-influenza compound, Zanamivir, reduced mortality and the expression of a fluorescent viral gene product, demonstrating the validity of this model to screen for potential antiviral drugs. The zebrafish model system has provided invaluable insights into host-pathogen interactions for a range of infectious diseases. Here, we demonstrate a novel use of this species for IAV research. This model has great potential to advance our understanding of influenza infection and the associated host innate immune response.

1 September 2017 in Immunity
Verified
Journal Article
Closed access
WMWalter K. Mowel
Walter K. Mowel
SMSam J. McCright
Sam J. McCright
JKJonathan J. Kotzin
Jonathan J. Kotzin
MCMagalie A. Collet
Magalie A. Collet
AUAsli Uyar
Asli Uyar
JHJorge Henao-Mejia
Jorge Henao-Mejia

28 May 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JKJonathan J. Kotzin
Jonathan J. Kotzin
FIFany Iseka
Fany Iseka
JWJasmine Wright
Jasmine Wright
MBMegha G. Basavappa
Megha G. Basavappa
MCMegan L. Clark
Megan L. Clark
JHJorge Henao-Mejia
Jorge Henao-Mejia
The transcriptional programs that regulate CD8 T-cell differentiation and function in the context of viral infections or tumor immune surveillance have been extensively studied; yet how long noncoding RNAs (lncRNAs) and the loci that transcribe them contribute to the regulation of CD8 T cells during viral infections remains largely unexplored. Here, we report that transcription of the lncRNA Morrbid is specifically induced by T-cell receptor (TCR) and type I IFN stimulation during the early stages of acute and chronic lymphocytic choriomeningitis virus (LCMV) infection. In response to type I IFN, the Morrbid RNA and its locus control CD8 T cell expansion, survival, and effector function by regulating the expression of the proapoptotic factor, Bcl2l11 , and by modulating the strength of the PI3K–AKT signaling pathway. Thus, our results demonstrate that inflammatory cue-responsive lncRNA loci represent fundamental mechanisms by which CD8 T cells are regulated in response to pathogens and potentially cancer.